ABOUT
TECHNOLOGY
Overview
Mechanism of Action
Pipeline
ADPKD
PATIENTS
INVESTORS
Overview
Press Releases
Events and Presentations
Financials & Filings
SEC Filings
Quarterly Results
Corporate Governance
Governance Documents
Board of Directors
Committee Composition
Analyst Coverage
Stock Information
Historical Stock Price
Investment Calculator
Insider Transactions
Fundamentals
Form 8937
Investor FAQs
Contact Us
CAREER
Toggle nav
Press Releases
.
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Investor Alerts
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
November 07, 2024
Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates
October 08, 2024
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
August 28, 2024
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
August 08, 2024
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates
August 06, 2024
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
64
»
